1、White PaperSEA and Pakistan:Emerging Hub for Vaccine Clinical Trials RAINA SINGH PAPLIKAR,Head,Marketing and Corporate Communications,R&D Solutions,IQVIA APACCECILIA WONG,Marketing Manager,R&D Solutions,IQVIA APACA strategic perspective for clinical development in Southeast Asia and Pakistan.Table o

2、f contentsExecutive summary 1SEA and Pakistans clinical trial emergence 1SEA and Pakistans operational strengths and vaccine trial readiness 2Country-level readiness and insights 5Accelerating global vaccine access:SEA and Pakistans regulatory modernisation and public health alignment 6Why SEA and P

3、akistan is the next hotspot for vaccine development 6What IQVIA Offers:Integrated support for vaccine clinical trial partners in SEA and Pakistan 7Conclusion 9Acknowledgment 9References 10About the authors 11SEA and Pakistans clinical trial emergenceThe urgency to shorten vaccine development timelin

4、es without compromising data quality has pushed global organizations developing new treatments to explore new geographies.SEA and Pakistan offer a compelling environment due to their population diversity,real-world healthcare settings,and active disease transmission in vaccine-relevant areas.With ov

5、er 900 million residents and endemic diseases such as tuberculosis,hepatitis,dengue,and RSV,SEA and Pakistan are naturally aligned with current vaccine development priorities.The region has transitioned from being a cost-effective outsourcing destination to a hub of scientific and regulatory capabil

6、ity.National authorities have updated their regulatory frameworks,reduced approval timelines,and adopted ICH-aligned practices,creating a robust environment for clinical development.To highlight these developments,IQVIA hosted an expert panel in June 2025 featuring regulators,investigators,and clini